The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
Dr. Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr. Mark J. O'Connor, Prof. Charlie Gourley, Dr. Judith Balmaña, Prof. Sibylle Loibl
DDR and PARPi BluePrint documents have been developed under the guidance of a Steering Committee with expertise in the field of DDR and PARP inhibition (PARPi).
BluePrint Resource |
min
|
Sep 2021
I agree that this educational programme:
These BluePrints are a reference guide to key aspects of PARPi and DDR and their role in oncology.
A variety of topics are covered, including the role of DDR in oncology, synthetic lethality, use of PARPi in oncology, efficacy and safety of currently approved PARP inhibitors, and the role of combination therapy with PARPi.
Other programmes of interest
Other programmes developed by Dr. Violeta Serra
Dr. Violeta Serra
Senior Scientist
Vall d'Hebron Institute of Oncology
Spain
Other programmes developed by Prof. Jonathan A. Ledermann
Prof. Jonathan A. Ledermann
Medical Oncologist
UCL Cancer Institute
United Kingdom (UK)
Other programmes developed by Prof. Eric Pujade-Lauraine
Prof. Eric Pujade-Lauraine
Gynaecologic Oncologist
Hôpital Hôtel-Dieu
France
Other programmes developed by Prof. Simon Boulton
Prof. Simon Boulton
Senior Scientist
Francis Crick Institute
United Kingdom (UK)
Other programmes developed by Prof. Charlie Gourley
Prof. Charlie Gourley
Medical Oncologist
CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Re...
United Kingdom (UK)
Other programmes developed by Dr. Judith Balmaña
Dr. Judith Balmaña
Medical Oncologist
Vall d'Hebron University Hospital
Spain